Ekso Bionics Holdings, Inc.
EKSO · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.04 | -0.00 | 0.62 | -0.41 |
| FCF Yield | -14.99% | -48.02% | -1.28% | -0.64% |
| EV / EBITDA | -13.24 | -3.23 | -43.95 | -76.10 |
| Quality | ||||
| ROIC | -9.71% | -21.90% | -16.49% | -10.73% |
| Gross Margin | 60.30% | 39.82% | 53.51% | 53.32% |
| Cash Conversion Ratio | 1.45 | 1.27 | 0.68 | 0.42 |
| Growth | ||||
| Revenue 3-Year CAGR | -4.59% | -2.29% | 6.64% | 11.55% |
| Free Cash Flow Growth | 41.61% | -75.27% | -35.14% | 36.37% |
| Safety | ||||
| Net Debt / EBITDA | -0.29 | -0.07 | 0.71 | 0.17 |
| Interest Coverage | -77.89 | -61.15 | -47.78 | -37.80 |
| Efficiency | ||||
| Inventory Turnover | 0.33 | 0.23 | 0.32 | 0.52 |
| Cash Conversion Cycle | 309.09 | 488.47 | 342.15 | 242.34 |